Syapse reposted this
This year's ASCO meeting underscored what an exciting time this is for advancements in cancer research, and cancer medicine, and the important impact that this work has for patients with cancer. One of the driving themes of this meeting is the rapid evolution of Precision Oncology, with existing targeted therapies moving “up-stream” to early stage disease. This resulting in a direct impact on cure rates, along with an increasing number of biomarkers and associated druggable targets that are rapidly advancing the development of new cancer treatments. RWD was a continuing topic at ASCO. An ever important tool in advancing therapies is the leveraging of RWD to support patient care, along with supporting regulatory submissions to the FDA. With regard to patient care, RWD can help assess the compliance with rapidly evolving patient care guidelines, showing the adoption rate of newly approved targeted therapies, and the testing rates for their respective companion diagnostics. RWD also allows for post-approval evaluation of safety and efficacy in the broader population, thus helping to address health care disparities, to include assessing the impact of social determinants of health. During this exciting time, we at Syapse continue to be dedicated to our health system and life science partners in lessening the burden of cancer for all populations.